Annual Accounts Payable
$1.55 M
-$926.00 K-37.44%
March 31, 2024
Summary
- As of February 26, 2025, VTGN annual accounts payable is $1.55 million, with the most recent change of -$926.00 thousand (-37.44%) on March 31, 2024.
- During the last 3 years, VTGN annual accounts payable has risen by +$708.70 thousand (+84.54%).
- VTGN annual accounts payable is now -43.92% below its all-time high of $2.76 million, reached on March 31, 2022.
Performance
VTGN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$1.04 M
+$324.00 K+45.31%
December 31, 2024
Summary
- As of February 26, 2025, VTGN quarterly accounts payable is $1.04 million, with the most recent change of +$324.00 thousand (+45.31%) on December 31, 2024.
- Over the past year, VTGN quarterly accounts payable has dropped by -$170.00 thousand (-14.06%).
- VTGN quarterly accounts payable is now -81.02% below its all-time high of $5.47 million, reached on June 30, 2022.
Performance
VTGN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
VTGN Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -37.4% | -14.1% |
| 3 y3 years | +84.5% | -14.1% |
| 5 y5 years | +46.6% | -14.1% |
VTGN Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.9% | +84.5% | -81.0% | +45.3% |
| 5 y | 5-year | -43.9% | +84.5% | -81.0% | +45.3% |
| alltime | all time | -43.9% | >+9999.0% | -81.0% | >+9999.0% |
VistaGen Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $1.04 M(+45.3%) |
| Sep 2024 | - | $715.00 K(-40.9%) |
| Jun 2024 | - | $1.21 M(-21.8%) |
| Mar 2024 | $1.55 M(-37.4%) | $1.55 M(-10.9%) |
| Dec 2023 | - | $1.74 M(+33.1%) |
| Sep 2023 | - | $1.30 M(-19.6%) |
| Jun 2023 | - | $1.62 M(-34.4%) |
| Mar 2023 | $2.47 M(-10.4%) | $2.47 M(+54.7%) |
| Dec 2022 | - | $1.60 M(-45.9%) |
| Sep 2022 | - | $2.96 M(-46.0%) |
| Jun 2022 | - | $5.47 M(+98.4%) |
| Mar 2022 | $2.76 M(+229.1%) | $2.76 M(+41.6%) |
| Dec 2021 | - | $1.95 M(-26.7%) |
| Sep 2021 | - | $2.66 M(+14.8%) |
| Jun 2021 | - | $2.32 M(+176.3%) |
| Mar 2021 | $838.30 K(-54.4%) | $838.30 K(+8.0%) |
| Dec 2020 | - | $776.40 K(-34.0%) |
| Sep 2020 | - | $1.18 M(-10.0%) |
| Jun 2020 | - | $1.31 M(-28.8%) |
| Mar 2020 | $1.84 M(+74.1%) | $1.84 M(+14.0%) |
| Dec 2019 | - | $1.61 M(+11.1%) |
| Sep 2019 | - | $1.45 M(+55.2%) |
| Jun 2019 | - | $933.90 K(-11.5%) |
| Mar 2019 | $1.05 M(-11.8%) | $1.05 M(-2.9%) |
| Dec 2018 | - | $1.09 M(+84.2%) |
| Sep 2018 | - | $590.10 K(-6.3%) |
| Jun 2018 | - | $629.50 K(-47.4%) |
| Mar 2018 | $1.20 M(+37.9%) | $1.20 M(+134.8%) |
| Dec 2017 | - | $509.30 K(-55.8%) |
| Sep 2017 | - | $1.15 M(+82.1%) |
| Jun 2017 | - | $632.00 K(-27.1%) |
| Mar 2017 | $867.30 K | $867.30 K(-0.8%) |
| Dec 2016 | - | $874.40 K(-6.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $930.20 K(+0.0%) |
| Jun 2016 | - | $930.10 K(-0.6%) |
| Mar 2016 | $936.00 K(-58.4%) | $936.00 K(-14.7%) |
| Dec 2015 | - | $1.10 M(-1.1%) |
| Sep 2015 | - | $1.11 M(-28.4%) |
| Jun 2015 | - | $1.55 M(-31.2%) |
| Mar 2015 | $2.25 M(-7.9%) | $2.25 M(-6.8%) |
| Dec 2014 | - | $2.42 M(+7.5%) |
| Sep 2014 | - | $2.25 M(+18.2%) |
| Jun 2014 | - | $1.90 M(-22.2%) |
| Mar 2014 | $2.44 M(+80.5%) | $2.44 M(+8.3%) |
| Dec 2013 | - | $2.26 M(+13.7%) |
| Sep 2013 | - | $1.98 M(+12.8%) |
| Jun 2013 | - | $1.76 M(+29.9%) |
| Mar 2013 | $1.35 M(-22.7%) | $1.35 M(+8.1%) |
| Dec 2012 | - | $1.25 M(-15.0%) |
| Sep 2012 | - | $1.47 M(-42.5%) |
| Jun 2012 | - | $2.56 M(+46.4%) |
| Mar 2012 | $1.75 M(>+9900.0%) | $1.75 M(+68.1%) |
| Dec 2011 | - | $1.04 M(-16.0%) |
| Sep 2011 | - | $1.24 M(+31.5%) |
| Jun 2011 | - | $943.20 K(>+9900.0%) |
| Mar 2011 | - | $6200.00(+129.6%) |
| Dec 2010 | $2700.00(+170.0%) | $2700.00(-6.9%) |
| Sep 2010 | - | $2900.00(+190.0%) |
| Jun 2010 | - | $1000.00(-73.0%) |
| Mar 2010 | - | $3700.00(+270.0%) |
| Dec 2009 | $1000.00(-54.5%) | $1000.00(-54.5%) |
| Sep 2009 | - | $2200.00(+120.0%) |
| Jun 2009 | - | $1000.00(-54.5%) |
| Dec 2008 | $2200.00 | $2200.00(-31.3%) |
| Jun 2008 | - | $3200.00(+45.5%) |
| Mar 2008 | - | $2200.00 |
FAQ
- What is VistaGen Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual accounts payable year-on-year change?
- What is VistaGen Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly accounts payable year-on-year change?
What is VistaGen Therapeutics annual accounts payable?
The current annual accounts payable of VTGN is $1.55 M
What is the all time high annual accounts payable for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual accounts payable is $2.76 M
What is VistaGen Therapeutics annual accounts payable year-on-year change?
Over the past year, VTGN annual accounts payable has changed by -$926.00 K (-37.44%)
What is VistaGen Therapeutics quarterly accounts payable?
The current quarterly accounts payable of VTGN is $1.04 M
What is the all time high quarterly accounts payable for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly accounts payable is $5.47 M
What is VistaGen Therapeutics quarterly accounts payable year-on-year change?
Over the past year, VTGN quarterly accounts payable has changed by -$170.00 K (-14.06%)